Skip to main content Skip to search Skip to main navigation
Flask High Quality Molecules
Truck Fast Delivery
Award Trusted by Researchers
Follow us: LinkedIn Contact Security

Cyclopentane

  • High-purity Cyclopentane
  • Extensive range of Cyclopentane
  • Ideal for drug discovery applications and organic synthesis
  • Fast delivery and expert support
Cyclopentane compounds are essential building blocks in pharmaceutical research. Our carefully curated selection offers diverse structures for SAR studies and lead optimization, ensuring quality and reliability for your projects.

Understanding Cyclopentane in Modern Chemistry

Explore the critical role of Cyclopentane in pharmaceutical development, medicinal chemistry research and organic chemistry.

Precision Chemistry

Precision Chemistry

Advanced synthesis techniques for superior quality compounds

Great Molecules for Chemical Diversity

Our catalogue of building blocks contains a diverse range of highly functionalised and decorated compounds. The 20 years of experience in supplying cutting-edge building blocks have given us the expertise to bring you the most exciting chemical motifs, adding chemical diversity to your projects.

Our diverse catalogue is tailored for medicinal chemistry, small molecule drug discovery and organic synthesis. Our unique range of Cyclopentane adds value to any research project.

We constantly add to our catalogue; the latest additions include a range of new Cyclopentane. We continue to bring you the latest and most exciting chemical compounds.

Quality Assurance

Quality Assurance

Every Cyclopentane product in our portfolio undergoes rigorous quality control testing. Our building blocks are supplied with the highest purity standards. We provide complete analytical characterisation, including:

  • ¹H and ¹³C NMR spectroscopy for structural verification
  • HPLC chromatograms confirming purity levels
  • Certificate of Analysis available.
  • Standard purity of 95%
  • Specific purity available upon request.

Diverse Applications

Diverse Applications

From oncology to neuroscience, enabling next-generation therapeutics

Over 2000 Cyclopentane in our catalogue
Found in over 30 FDA-approved drugs
95% of compounds available from stock

Cyclopentane products in our portfolio

The cyclopentane ring occupies a well-established position in small-molecule drug discovery, drawing much of its value from its prevalence across bioactive natural products and its structural similarity to the ribose sugar found in nucleosides. The cyclopentane motif has been utilised as an effective core scaffold for several highly successful medicinal chemistry programmes, providing underappreciated yet significant value for biomedical research. Unlike more strained carbocycles, cyclopentane adopts a low-strain pseudo-envelope conformation that reduces torsional penalties, supports multiple stereocentres, and presents substituents with well-defined directionality. These properties make it well suited to conformational restriction strategies, where locking a flexible acyclic chain or replacing a metabolically labile group can sharpen target engagement and improve selectivity.

Across therapeutic areas, cyclopentane has found application in antiviral, cardiovascular, oncology, and immunology programmes, including as a carbocyclic mimic of the ribose ring in nucleoside analogues and as a hydrophobic pocket-filling element in kinase inhibitors. Ticagrelor (Brilinta, AstraZeneca), a direct-acting P2Y12 receptor antagonist in the cyclopentyltriazolopyrimidine chemical class, was approved by the FDA in July 2011 as the first reversibly binding oral ADP receptor antagonist for the reduction of cardiovascular death and myocardial infarction in patients with acute coronary syndrome. Deuruxolitinib (Leqselvi, Sun Pharma), approved by the FDA in July 2024 for the treatment of severe alopecia areata in adults, is an oral JAK1 and JAK2 inhibitor in which selective deuteration of the cyclopentyl ring significantly improves pharmacokinetic properties relative to ruxolitinib.

Our range of cyclopentanes features novel substitutions and the incorporation of synthetically tractable functional groups such as boronic acids and esters, amines, carboxylic acids, ketones, hydroxyls and halogens to enable expedient synthetic strategies.

Please examine a selection of cyclopentanes in our catalogue. The full range can be found using the substructure feature of our Search tools.

Frequently Asked Questions

Common questions about our Cyclopentane products.

Cyclopentane is a five-membered saturated carbocyclic ring that occupies a well-established position in small-molecule drug discovery, drawing much of its value from its prevalence across bioactive natural products and its structural similarity to the ribose sugar found in nucleosides. Unlike more strained carbocycles, cyclopentane adopts a low-strain pseudo-envelope conformation that reduces torsional penalties, supports multiple stereocentres, and presents substituents with well-defined directionality. These properties make it well suited to conformational restriction strategies aimed at sharpening target engagement and improving selectivity.

The cyclopentane ring closely resembles the ribose furanose ring found in nucleosides, making it a natural starting point for carbocyclic analogues of nucleoside antivirals that are resistant to phosphorolytic cleavage at the glycosidic bond. Carbocyclic nucleoside analogues incorporating cyclopentane in place of ribose retain the spatial presentation of the base and the 5-hydroxymethyl group required for kinase phosphorylation, while gaining the metabolic stability that comes from replacing the ring oxygen with a methylene group. This design strategy has been applied across antiviral, cardiovascular, and oncology programmes.
The pseudo-envelope conformation of cyclopentane arises from the ring adopting a shape in which four carbons are approximately coplanar and one is puckered out of the plane. This low-strain conformation reduces torsional penalties while allowing substituents to be presented at well-defined spatial positions with predictable directionality. For drug design, this means that stereocentres introduced on the ring project pharmacophoric groups into defined regions of three-dimensional space, supporting selective engagement with topographically defined binding pockets.
Two notable FDA-approved drugs incorporate cyclopentane. Ticagrelor (Brilinta, AstraZeneca), a direct-acting P2Y12 receptor antagonist in the cyclopentyltriazolopyrimidine chemical class, was approved by the FDA in July 2011 as the first reversibly binding oral ADP receptor antagonist for reducing cardiovascular death and myocardial infarction in patients with acute coronary syndrome. Deuruxolitinib (Leqselvi, Sun Pharma), approved by the FDA in July 2024 for severe alopecia areata in adults, is an oral JAK1 and JAK2 inhibitor in which selective deuteration of the cyclopentyl ring significantly improves pharmacokinetic properties relative to ruxolitinib.
Ticagrelor is classified as a cyclopentyltriazolopyrimidine, where the cyclopentyl group is directly fused to the triazolopyrimidine hinge-binding pharmacophore. As the first reversibly binding oral P2Y12 receptor antagonist, ticagrelor's approval in 2011 represented a mechanistic advance over the irreversible thienopyridine class. The cyclopentyl ring contributes to the three-dimensional shape that enables the molecule to bind and dissociate from the P2Y12 receptor in a reversible manner, offering a more controllable antiplatelet effect than irreversible agents.
Deuruxolitinib is an oral JAK1 and JAK2 inhibitor in which selective deuteration of the cyclopentyl ring of the ruxolitinib scaffold significantly improves pharmacokinetic properties. Deuterium substitution at metabolically vulnerable C-H positions on the ring slows cytochrome P450-mediated oxidation through the kinetic isotope effect, reducing metabolic clearance and extending the half-life. This improved pharmacokinetic profile enables effective JAK inhibition for the treatment of severe alopecia areata with a dosing regimen that may offer advantages over the parent compound.
Cyclopentane has found application in antiviral, cardiovascular, oncology, and immunology programmes, including as a carbocyclic mimic of the ribose ring in nucleoside analogues and as a hydrophobic pocket-filling element in kinase inhibitors. Its low ring strain, ability to support multiple stereocentres, and structural relationship to biologically abundant sugar rings give it broad relevance. The scaffold is particularly well represented in programmes where conformational restriction of a flexible acyclic chain or replacement of a metabolically labile group is required to sharpen target engagement.

Still have questions?

Our technical support team is here to help with any inquiries about our Cyclopentane products.